Format

Send to

Choose Destination
See comment in PubMed Commons below
Immunotherapy. 2009 Nov;1(6):949-64. doi: 10.2217/imt.09.70.

Toll-like receptor agonists in cancer therapy.

Author information

1
NYU Cancer Institute, New York, NY 10016, USA. sylvia.adams@nyumc.org

Abstract

Toll-like receptors (TLRs) are pattern-recognition receptors related to the Drosophila Toll protein. TLR activation alerts the immune system to microbial products and initiates innate and adaptive immune responses. The naturally powerful immunostimulatory property of TLR agonists can be exploited for active immunotherapy against cancer. Antitumor activity has been demonstrated in several cancers, and TLR agonists are now undergoing extensive clinical investigation. This review discusses recent advances in the field and highlights potential opportunities for the clinical development of TLR agonists as single agent immunomodulators, vaccine adjuvants and in combination with conventional cancer therapies.

KEYWORDS:

CpG; Toll-like receptor; Toll-like receptor agonist; bacillus Calmette–Guerin; imiquimod; immunotherapy; monophosphoryl lipid A; polyriboinosinic-polyribocytidylic acid; resiquimod; vaccine adjuvant

PMID:
20563267
PMCID:
PMC2886992
DOI:
10.2217/imt.09.70
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center